These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15721412)

  • 1. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
    Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK
    Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
    Merritt MA; Parsons PG; Newton TR; Martyn AC; Webb PM; Green AC; Papadimos DJ; Boyle GM
    BMC Cancer; 2009 Oct; 9():378. PubMed ID: 19849863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
    Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
    J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer.
    Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y
    Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.